Author/Authors
beysel, selvihan afyonkarahisar sağlık bilimleri üniversitesi - tıp fakültesi - endokrinoloji ve metabolizma bilim dalı, Turkey , çalişkan, mustafa atatürk düzce devlet hastanesi - endokrinoloji ve metabolizma kliniği, Turkey , kizilgül, muhammed dışkapı yıldırım beyazıt eğitim araştırma hastanesi - endokrinoloji ve metabolizma kliniği, Turkey , özçelik, özgür ankara şehir hastanesi - endokronoloji ve metabolizma kliniği, Turkey , çilekar, murat afyonkarahisar sağlık bilimleri üniversitesi - tıp fakültesi - genel cerrahi anabilim dalı, Turkey , özbek, mustafa dışkapı yıldırım beyazıt eğitim araştırma hastanesi - endokrinoloji ve metabolizma kliniğ, Turkey , çakal, erman dışkapı yıldırım beyazıt eğitim araştırma hastanesi - endokrinoloji ve metabolizma kliniğ, Turkey
Title Of Article
MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS
شماره ركورد
42341
Abstract
OBJECTIVE: The monocyte count to HDL-Cholesterol ratio (MHR) was increased in patients with cardiovascular disease and, showed as an indicator of cardiovascular risk factors. Functional adrenal tumor and even nonfunctional adrenal adenomas are associated with an increased risk for cardiovascular disease. This is the first study to evaluate the MHR value in patients with adrenal tumors, and examine its relation with cardiometabolic risk factors. MATERIAL AND METHODS: Twenty-four patients with functional adrenal tumor (10 Cushing syndrome, 12 pheochromocytoma, and 2 primary hyperaldosteronism), patients with non- functional adrenal adenoma (n=33) and, control subjects (n=50) were included. Anthropometric, hormonal and biochemical results, lipid panel, fasting plasma glucose (FPG), blood pressure (BP), blood cell counts, high-sensitivity C-reactive protein (hs-CRP), and carotid intima-media thickness (CIMT) were compared. RESULTS: Mean age (51.14±2.03 vs 54.01±9.37 years), sex distribution (female 66.7 % vs 73.8 %), and body mass index (31.12±3.38 vs 30.46±2.96 kg/m2) were similar between adrenal tumor and control group (respectively, p 0.05). The MHR value was higher in the functional tumor group compared with the non-functional adenoma and control group (13.79±3.14, 10.19±2.84 vs 10.08±1.82, respectively, p 0.05). MHR value was similar between the non-functional adenoma and controls (p 0.05). MHR value was positively correlated with systolic BP (r=0.480, p 0.001), diastolic BP (r=0.452, p 0.001), FPG (r=0.333, p=0.001), hs-CRP (r=0.538, p=0.001) and, urinary normetanephrine concentrations (r=0.302, p=0.043). Functional adrenal tumor with cardiovascular disease had higher MHR value compared with those without cardiovascular disease (14.69±2.67 vs 11.84±2.57, p 0.05). CONCLUSIONS: The MHR value was increased in patients with functional adrenal tumor; however it did not increase in patients with nonfunctional adenoma. MHR value was correlated with cardio-metabolic risk factors such as FPG, BP, and hs-CRP. The MHR value suggests as a predictive marker for cardiometabolic risk factors in functional adrenal tumors.
From Page
201
NaturalLanguageKeyword
Monocyte count to HDL , C ratio , Cardiometabolic risk factors , Adrenal tumor
JournalTitle
Kocatepe Medical Journal
To Page
207
JournalTitle
Kocatepe Medical Journal
Link To Document